Hiroki Hidejima
Director/Board Member presso METAREAL CORPORATION
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Hiroki Hidejima is currently a Director at several companies including HuBit Genomix KK, THANN Natural KK, BioComo, Inc., C.H.C.
SYSTEM Co., Ltd., and Development Association For Youthleaders.
He is also an Outside Director at Metareal Corp.
and an Auditor at YES-fm KK.
He received his undergraduate degree from Kobe University Graduate School of Business Administration in 1973.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
METAREAL CORP.
1.93% | 31/08/2023 | 207 500 ( 1.93% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Hiroki Hidejima
Società | Posizione | Inizio |
---|---|---|
METAREAL CORPORATION | Director/Board Member | 01/04/2004 |
J & I YK | Director/Board Member | 01/02/2004 |
YES-fm KK | Comptroller/Controller/Auditor | 01/03/2005 |
C.H.C. SYSTEM Co., Ltd. | Director/Board Member | 01/05/2005 |
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Director/Board Member | 01/07/2010 |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Director/Board Member | 01/06/2014 |
THANN Natural KK | Director/Board Member | 01/06/2012 |
Development Association For Youthleaders | Director/Board Member | 01/03/2004 |
Formazione di Hiroki Hidejima
Kobe University Graduate School of Business Administration | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 8 |
---|---|
HuBit Genomix KK
HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Commercial Services |
Metareal Corp. | |
C.H.C. SYSTEM Co., Ltd. | |
THANN Natural KK | |
J & I YK | |
YES-fm KK | |
BioComo, Inc.
BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Health Technology |
Development Association For Youthleaders |
- Borsa valori
- Insiders
- Hiroki Hidejima